SOEDAK2009 --- PREPARE FOR THE LONG RUN

Titel	Autor
Antiretroviral treatment outcomes and their predictors in a large cohort of HIV-Infected children in Sub-Saharan Africa	Maria Cristina Marazzi¹, Andrea De Luca², Massimo Magnano San Lio³, Ersilia Buonomo³, Paola Scarcella⁴, Paola Germano⁴, Gianni Guidotti⁴, Giovanna Paturzo⁴, An
Mortality of HIV-infected patients in the HAART era	Mario Sarcletti¹, Margret Jöchl², Stefanie Gogl³, Armin Rieger⁴, Maria Geit⁵, Bernhard Haas⁶, Robert Zangerle¹
Risk of new AIDS defining events in patients with advanced immunodeficiency during suppressive HAART	Alexander Zoufaly¹, Christina Kreuzberg¹, Matthias an der Heiden², Christian Kollan², Osamah Hamouda², Jan van Lunzen³
Erwartungen an den Arzt - optimale HIV/STD-Prävention aus der Sicht schwuler Männer	Angelika Wolf¹, Julika Loss¹, Steffen Taubert²
Trends in risk-taking and risk reduction among German MSM. Results of follow-up surveys “Gay Men and AIDS” 1991-2007	Axel J. Schmidt¹, Michael Bochow¹
HIV serosorting and the risk of sexually transmitted infections in men who have sex with men	Ulrich Marcus¹, Axel J. Schmidt¹
"EKAF" avant la lettre? ART-bezogene Risikomanagementstrategien bei MSM in Deutschland	Phil C. Langer¹, Jochen Drewes², Ursula von Rüden³, Angela Kühner^1,4
Zu den Kontexten von HIV-Neuinfektionen bei schwulen Männern in Berlin zwischen 2003 und 2006. Interviews mit Neuinfizierten	Michael Bochow¹
HIV-exponierte Schwangerschaften an zwei deutschen Schwerpunktzentren 2004 - 2008	Andrea Gingelmaier¹, Ralph Kästner¹, Milena Sovric¹, Jan-Peter Siedentopf², Cornelia Feiterna-Sperling³, Gundula Notheis⁴, Weizsäcker Katharina²
Association of effective control of HIV-1 with strong ctl selection pressure and a highly mutated nef in a HIV-1-infected patient	Katja Maurer¹, Jan Schmökel², Frank Kirchhoff², Jennifer Etschel¹, Sascha Antoni³, Kathrin Eismann¹, Silke Bergmann¹, Pia Rauch¹, Karin Metzner⁴
Very rapid resonse kinetics to HLA-B57/58 gag-restricted CTL epitopes is asociated with slow diesease progression	Jan van Lunzen^1,2, Julian Schulze zur Wiesch^1,2, Philip Hartjen^1,2, Ingrid Stahmer^1,2
HLA-E restringierte Erkennung eines HIV-Peptids durch humane CD8(+) T-Zellen	Daniela Schulte¹, Martin Vogel¹, Bettina Langhans¹, Christian Körner¹, Benjamin Krämer¹, Hans Dieter Nischalke¹, Martin Coenen¹, Tilman Sauerbruch^1<
Frequency and phenotype of CD4+ FoxP3+ T regulatory cells is associated with disease progression in HIV-1 infected patients	Adriana Thomssen¹, Philipp Hartjen¹, Sandra Hertling¹, Olaf Degen¹, Stefan Schmiedel¹, Dirk Meyer-Olsen², Ansgar Lohse¹, Joachim Hauber³, Jan van Lunze
Scheitert eine adäquate ökonomische Abbildung der stationären HIV-Fälle durch die G-DRGs an der niedrigen Prävalenz der HIV-Infektion in Deutschland?	Matthias Stoll¹, Deutsche AIDS Gesellschaft
Direct costs for highly active antiretroviral treatment (HAART) regimens in the German ClinSurv multicenter cohort 1996 - 2008*	Matthias Stoll¹, Christian Kollan², Osamah Hamouda², ClinSurv Study Group
Risk factors of "early“ and "late“ diagnosis of HIV infection in Austria	Mario Sarcletti¹, Stefanie Gogl², Margret Jöchl³, Armin Rieger⁴, Maria Geit⁵, Bernhard Haas⁶, Ninon Taylor⁷, Manfred Kanatschnig⁸, Robert Zangerle
Prevalence of potential drug-drug interactions in the Swiss HIV Cohort Study	Catia Marzolini¹, Sara Gibbons², Luigia Elzi¹, Saye Khoo², Bruno Ledergerber³, David Back², Manuel Battegay¹, Swiss HIV Cohort Study Members
Clinical outcomes of HIV-positive patients (PLWHA) having different income status: results of an analysis on basis of the KompNet cohort	Klaus Jansen¹, Norbert H. Brockmeyer^1,2, Verena Dlugay³, Matthias Stoll⁴, Ramona Volkert⁵, Jörg Gölz⁶, Thomas Buhk⁷, Andreas Carganico⁸, Peter
The influence of nucleoside free HAART on the treatment of chronic hepatitis C with pegylated interferon / ribavirin combination treatment	Martin Vogel¹, Golo Ahlenstiel¹, Gerd Klausen², Thomas Lutz³, Dirk Schürmann⁴, Christoph Stephan⁵, Christoph Mayr⁶, Axel Baumgarten⁷, Peter Buggis
Successful antiretroviral therapy is associated with increasing HCV-specific T cell responses	Janine Rohrbach¹, Gillian Harcourt², Silvana Gaudieri³, Nicola Robinson², Amalio Telenti⁴, Matthias Egger⁵, Huldrych Günthard⁶, Paul Klenerman², Hansjakob
Retrospective analysis of orthotopic liver transplantation in human immunodeficiency virus (HIV)-Positive patients in German transplant centers	Evrim Anadol¹, Christoph Berg², Markus Bickel³, Bernd Salzberger⁴, Matthias Stoll⁵, Alexander Zoufaly⁶, German OLTX-HIV-Group
Outcome of AIDS-related lymphoma depends on CD20 expression	Christoph Wyen¹, Gerd Fätkenheuer¹, Björn-Erik Ole Jensen², Michael Sabranski³, Timo Wolf⁴, Jan Siehl⁵, Birgit Ross⁶, Markus Müller⁷, J
HIV-associated Hodgkin's lymphoma (HIV-HL): Interim analysis of a prospective multicenter trial	Marcus Hentrich¹, Anja Masuhr², Christoph Wyen³, Jan Siehl⁴, Timo Wolf⁵, Jan-Christian Wasmuth⁶, Ansgar Rieke⁷, Dagmar Assmann⁸, Anke Meyer⁹
Low sensitivity of an interferon-gamma releasing assay (Elispot-TB) for the diagnosis of latent tuberculosis in HIV-infected individuals	Luigia Elzi¹, Ingrid Steffen², Hansjakob Furrer³, Stefano Bassetti⁴, Manuel Battegay¹
**Specific *HIV-1 env* traits and association with** virologic control in vivo**	Beda Joos¹, Philip Rieder¹, Marek Fischer¹, Herbert Kuster¹, Peter Rusert², Alexandra Trkola², Satish K Pillai³, Joseph K Wong³, Rainer Weber¹
Genotypic activity of Etravirine in patients failing on Efavirenz or Nevirapine: the Swiss HIV cohort study (SHCS)	Alexandra U. Scherrer¹, Barbara Hasse¹, Viktor von Wyl¹, Sabine Yerly², Jürg Böni³, Philippe Bürgisser⁴, Thomas Klimkait⁵, Heiner C. Bucher⁶
Does the addition of rPRT to GRT help in choosing regimens with better virologic response?	Tracy Glass¹, Jan Fehr², Severine Louvel^3,4, Jürg Böni⁵, Sabine Yerly⁶, Philippe Bürgisser⁷, Heiner Bucher¹, Thomas Klimkait³
Targeting SEVI-mediated enhancement of virus infection to reduce sexual transmission of HIV-1	Ilona Hauber¹, Heinrich Hohenberg¹, Joachim Hauber¹
Control of HIV by CCR5Δ32/Δ32 stem cell transplantation - an update	Kristina Allers¹, Gero Hütter², Jörg Hofmann³, Christoph Loddenkemper⁴, Thomas Schneider¹
Preclinical evaluation of VIR-576, a novel antiretroviral drug candidate blocking the HIV-1 gp41 fusion peptide	Wolf-Georg Forssmann¹, Knut Adermann², Ludger Ständker¹, Matthias Stoll¹, Yu-Han The¹, Frank Kirchhoff³, Jan Münch³, Reinhold Ernst Schmidt¹
A neutralizing monoclonal antibody for HIV gene therapy	Khalid Al-Shoba¹, Kimbel Janine¹, Lisa Egerer¹, Sebastian Newrzela¹, Tobias Maetzig², Axel Schambach², Dorothee von Laer¹
AIDS und Immigranten aus ehemaliger Sowjetunion (ESU): erste Erkenntnisse über Wissen und Inanspruchnahme von AIDS-Beratungsangeboten in Deutschland	Laura Kouznetsov¹, Alexander Vasilevich Kuznetsov², Thomas Ruzicka³, Stefan Zippel¹
What do men who have sex with men in Germany know about the most common sexually transmitted infections?	Ulrich Marcus¹, Axel J. Schmidt¹
Internetgestützte Sexualkontakte und HIV-Infektionsrisiko	Michael Bochow¹, Axel J. Schmidt²
Late and early presenters in the German KompNet Cohort - a comparison of sociodemographic variables	Ulrich Marcus¹, Claudia Michalik², Norbert Brockmeyer^3,4, Verena Duglay⁵, Martin Zeitz⁶, Elke Lauenroth-Mai⁷, Martin Hower⁸, Stefan Reuter⁹, Jürgen
Support needs and access to services relating to sexual and reproductive health of people living with HIV/AIDS (PLWHA) in Switzerland	Sibylle Nideröst¹, Daniel Gredig¹, Christophe Roulin¹, Martin Rickenbach², the Swiss HIV Cohort Study and the Eurosupport Study Group
Gender differences in social support and mental health among HIV positive women and men living in Europe	Christiana Nöstlinger¹, Victoria Gordillo², Erin Fekete³, Tom Platteau¹, Eurosupport V Study Group
Optimierung einer zielgerichteten, subsidiären Einzelhilfe durch die Deutsche AIDS Stiftung (DAS) durch eine Vernetzung mit Daten aus dem Kompetenznetz HIV/AIDS	Matthias Stoll¹, Volker Mertens², Claudia Michalik³, Klaus Jansen⁴, Norbert Brockmeyer⁵, Hans Jäger⁶, Andreas Plettenberg⁷, Arend Moll⁸, Stephan D
Perceived threat of HIV/Aids and knowledge of highly active antiretroviral therapy (HAART) in heterosexual men and MSM in Germany	Ursula von Rueden¹
HIV-related travel restrictions	David Hans-U. Haerry¹, Peter Wiessner¹, Karl Lemmen²
Chancen und Grenzen des Internet für eine erweiterte HIV/AIDS-Prävention, HIV- und STD-Beratung sowie Partizipation der Zielgruppen	Claudia Corsten¹
Keeping a grip on HIV: collaborative medication and symptom management experiences of persons living with HIV in Switzerland	Dunja Nicca^1,2, Jan Sven Fehr³, Pietro Vernazza⁴, Rebecca Spirig^5,6
Motivational patterns of HIV testing among MSM: Implications for prevention	Phil C. Langer¹, Jochen Drewes², Ursula von Rüden³
Gesundheitsbezogene Lebensqualität (QoL) HIV-positiver Patienten in einer Schwerpunktpraxis	Stefan Mauss¹, Julia Henke¹, Florian Berger¹, Petra Hegener¹, Guenther Schmutz¹
Die gesellschaftliche Regierung der HIV-Infektion. Eine empirisch-genealogische Studie	Katrina Pfundt¹
Niedrigschwellige Beratung von HIV-Patienten als interdisziplinäre Kooperation zwischen Ärzten von Schwerpunktpraxen und psychosozialen Beratern einer Selbsthilfeorganisation	Leo Locher^1,2, Gaby Knecht¹, Imke Klein², Michael Bohl²
HIV-related vulnerability dynamics and syndemic productions in homosexual life contexts	Phil C. Langer¹, Angela Kühner^1,2
Die hausärztliche Betreuung HIV-Positiver aus Sicht der betroffenen Patienten	Heike Nestel¹, Burkhard Schappert¹, Michael Jansky¹, Ulrich Seifert¹
Der kleine Unterschied - Symptomerfahrung bei HIV-positiven Personen mit oder ohne Bezugsperson	Katharina Fierz¹, Kimberly Moody², Dunja Nicca^3,4, Tracy Glass⁵, Manuel Battegay⁶, Rebecca Spirig^1,4
Fortbildungsbedarf von Hausärzten im Bezug auf HIV/AIDS	Burkhard Schappert¹, Michael Jansky¹, Stefan Graafen¹
Die Bedeutung von HIV in der hausärztlichen Praxis	Burkhard Schappert¹, Michael Jansky¹, Stefan Graafen¹
Ermittlung von Patientenpräferenzen bei der Therapie von HIV/AIDS	Matthias Nübling¹, Hans-Joachim Lincke¹, Verena Donatz², Axel Christian Mühlbacher¹, Kompetenznetz HIV
Lebensqualität von HIV/Aids Patienten und Patientinnen	Daniela Fuchs¹
HIV und Aids und Arbeit/Beschäftigung - Situation HIV-positiver Frauen in Deutschland	Gaby Wirz¹, Ulrike Sonnenberg-Schwan², Harriet Langanke³, Dagmar Klimesch⁴, Netzwerk Frauen und Aids Deutschland
Spiritual and mind-body beliefs as barriers and motivators to HIV-treatment decision-making and medication adherence?	Heidemarie Kremer¹, Gail Ironson¹, Martina Porr¹
Beyond being not wanting to be a guinea pig: barriers and motivators to participation of minority women in clinical trials	Heidemarie Kremer¹, Gail Ironson¹, Martina Porr^1,2
Coping-Prozesse bei HIV/AIDS-Patienten aus der Perspektive westlicher und buddhistischer Psychologie	Carsten Klöpfer¹
Preparing for the long run - Ein Wochenendseminar über HIV Therapie und Prävention für internationale Ärzte der nächsten Generation	Tessa S Lennemann¹, Rose Marie Beck², Christoph Königs³, Holger Pfister⁴, Gabriele Nisius¹, Mira Gruber¹, Lena Kroeker⁵, Reinhard Brodt⁶
Die Regierung der HIV-Infektion. Eine empirisch-genealogische Studie	Katrina Pfundt¹
A regional multi-sectoral HIV prevention and AIDS care programme approach to keep the Western Balkans low-prevalent	Bettina Schwethelm¹, LeeNah Hsu¹, Olimbi Hoxhaj², Genc Ymerhalili³
Public acceptence of harm reduction as a major limitation for HIV prevention in Bashkortostan	Zulfia Galieva¹, Dunja Nicca², Johannes Schläpfer³, Matthias Schlegel², Pietro Vernazza², Bettina Mäschli⁴, Infekt Team Schweiz Russland (ITSR)
Krankheit als Schuld: Paradigmenwechsel in der Medizin?	Stefan Nagel¹
Berührungsängste verlieren, Professionalität gewinnen - ein Trainingsprogramm des HIVCENTER für Lernende in Gesundheitsfachberufen	Kathleen Mantzsch¹, Patricia Luczkowski², Michaela Bracone¹, Tessa Lennemann¹, Claudia Kircher¹, H.R. Brodt¹
Ergebnisse einer kunsttherapeutischen Studie	Regine Merz¹, Norbert Brockmeyer², David Aldridge¹, Kompetenznetz HIV/AIDS
Working toward a world without AIDS: how social marketing inspires long-term cultural change	Ruth E. Massingill¹
Prävention für Menschen mit HIV: Sexualverhalten und beeinflussende Faktoren	Dunja Nicca¹, Synove Daneel¹, Pietro Vernazza¹
BuT - Beratung und Test: Ein landesweites Projekt zur HIV-Primärprävention in der Vorort-Arbeit für MSM in Nordrhein-Westfalen	Michael Wurm¹, Reinhard Klenke¹, Dirk Meyer¹
Mach�s mit 2009: Emotionen und Informationen - ein neues Kommunikationskonzept zur bevölkerungsweiten und zielgruppenspezifischen HIV/AIDS-Prävention	Claudia Corsten¹, Wolfgang Müller¹
Stufen der Partizipation in der HIV-Prävention	Michael T. Wright¹, Martina Block¹, Hella von Unger¹, Karl Lemmen²
Condom use among heterosexual HIV positive men and women: what's in a steady relationship? Results of the Eurosupport V study	Christiana Nöstlinger¹, Sibylle Nideröst², Daniel Gredig², Tom Platteau¹, Matthias Müller³, Eurosupport V Study Group & Swiss HIV Cohort Study
Glance over the fence - and back! BORDERNETWork- further development of hands-on HIV/AIDS/STI prevention, diagnostic and treatment in Europe	Elfriede Steffan¹, Tzvetina Arsova Netzelmann¹
How do we know what works? Assessment survey on quality assurance in the frame of National HIV/AIDS Prevention Programmes	Tzvetina Arsova Netzelmann¹, Elfriede Steffan¹, Helene Reemann²
Development of an HIV prevention flyer for illiterate persons and individuals with functional illiteracy	Synove Daneel¹, Adjara Tina², Johannes Schlaepfer³, Patrick Schmid⁴, Pietro Vernazza⁴, Dunja Nicca⁴
Perspektiven der HIV-Prävention mit vulnerablen Jugendlichen: Erfahrungen aus einem Modellprojekt im Berliner Jugendarrest	Thomas Wilke¹, Phil C. Langer¹, Birte Seffert¹, Stefan Müller¹, Dorothee Krings¹, Susann Bollmann¹, Christina Auffenberg¹, Nils Groß¹, Patrick
Mission possible - doch nicht möglich? Effekte der Aktion 3 Monate Safer Sex ein Jahr danach	Roger Staub¹, Steven Derendinger¹, Martin Gebhardt¹, Thomas Bucher², Christophe Fraser³, Hugues Balthasar⁴
Recurring patterns in safer sex discussions in forums of sex workers' clients	Harriet Langanke¹
Feasibility study for a European internet platform in the field of HIV prevention and sexual health	Christiane Firnges¹, Elfriede Steffan¹, Ursula von Rüden²
Safe Environment. (SE) Entwicklung von Standards zur HIV-Prävention in kommerziellen Sex-Betrieben für MSM. Leitfaden zur Standardisierung und bundesweiten Umsetzung	Franz-Josef Ehrle¹, Herbert Engel¹
“Hard to reach” oder how to reach - anonymer HIV-Test für Migrantinnen in unterschiedlichen Settings	Heidrun Nitschke¹, Anna Knappik¹, Jan Leidel²
Die Rolle der Postexpositions-Prophylaxe in der Prävention mit MSM: Ergebnisse einer Befragung von HIV-Schwerpunktärzten	Jochen Drewes¹, Phil C. Langer², und das Kompetenznetz HIV/Aids
Ergebnisse einer Befragung der Aidshilfen zu Partizipation und Kooperation in der HIV-Prävention mit Migrant/innen	Hella von Unger¹, Silke Klumb², Michael T Wright¹
Anonyme HIV-Testberatung und Migrantinnen - wer findet den Weg?	Heidrun Nitschke¹, Anna Knappik¹, Jan Leidel²
Klientenorientierte Erhebung zum HIV-Test-Angebot (Hintergründe und Motivation); Orientierung zur Verbesserung des Angebots	Dagmar Charrier¹
Die Deutsch-Ukrainische Zusammenarbeit im Bereich HIV/AIDS	Jenny Bluhm¹
Microbicide formulations in development	Thomas Mertenskoetter¹, Joseph Romano¹, Paulina Kaptur¹
Internet-Plattform zur Partizipativen Qualitätsentwicklung (PQE) in der HIV-Prävention	Hella von Unger¹, Corinna Gekeler², Martina Block¹, Karl Lemmen², Michael T Wright¹
Nachwuchsförderung im HIVCENTER - Medizinstudenten als Zielgruppe für HIV Prävention und praktische medizinische Ausbildung	Claudia Kircher¹, Sebastian Kessler¹, Nathalie Schmitz², Tobias Kisch², Reinhard Brodt³, Tessa Lennemann¹
�Handbuch Jugendprävention“: ein neues Instrument der Qualitätssicherung in der Präventionsarbeit	Thomas Wilke¹, Phil C. Langer², Birte Seffert³, Stefan Müller³, Sarah Arriagada², Robin Möser², Stefan Richter², Franziska Gutsche², Schoolwor
HIV-Infektion im Bewusstsein von Studierenden: Ergebnisse einer Pilotstudie	Alexander Vasilevich Kuznetsov^1,2, Laura Kouznetsov¹, Uwe Matterne³, Rafael Mikolajczyk², Thomas Ruzicka⁴, Stefan Albin Zippel⁵, Alexander Krämer⁶
Molecular epidemiology reveals long-term changes in HIV-1 transmission in Switzerland	Roger Kouyos¹, Viktor von Wyl¹, Sabine Yerly², Jürg Böni³, Patrick Taffé⁴, Cyril Shah³, Philippe Bürgisser⁵, Thomas Klimkait⁶, Raine
HIV-serosorting among German men who have sex with men. Implications for community prevalence of STIs and HIV-prevention	Axel J. Schmidt¹, Ulrich Marcus², Jürgen Töppich³, Michael Bochow¹
First preliminary results and operational findings from the German HIV incidence study at Robert Koch-Institute	Ruth Zimmermann¹, Jörg Bätzing-Feigenbaum¹, Stephan Loschen², Silvia Gohlke-Micknis¹, Oscar Kamga Wambo¹, Claudia Kücherer², Osamah Hamouda¹
Epidemiology of herpes simplex virus infections (HSV) in a cohort of recently HIV-1 infected patients from the German HIV-1 seroconverter study	Christina Lindemann¹, Claudia Houareau¹, Nadine Spielmann¹, Barbara Bartmeyer¹, Claudia Kücherer², Osamah Hamouda¹, German HIV-1 Seroconverter Group
Line-immunoassay-based differentiation of recent and older HIV-1 infection among all newly diagnosed patients in Switzerland	Jörg Schüpbach¹, Christoph Niederhauser², Sabine Yerly³, Stephan Regenass⁴, Lukas Matter⁵, Philippe Bürgisser⁶, Meri Gorgievski⁷, Ingrid Steffen
Stable percentages of CD4⁺ and CD8⁺ T-cell in Elite Controllers, but not intermediate Controllers of HIV-1 replication	Clara Lehmann¹, Pia Flossdorf¹, Dirk Meyer-Olson², Reinhold E Schmidt², Pavel Khaykin³, Stefan Mauss⁴, Jan van Lunzen⁵, Christoph Stefan³, Juergen Rock
Risk factors for HIV associated Hodgkin's lymphoma during HAART in a large observational study (ClinSurv)	Alexander Zoufaly¹, Hans-Jürgen Stellbrink², Matthias an der Heiden³, Christian Kollan³, Christoph Wyen⁴, Christian Hoffmann², Jan van Lunzen⁵, Osamah Hamouda
The connection domain mutation N348I in HIV-1 reverse transcriptase may compensate for M184V-mediated deficits in viral fitness	Viktor von Wyl¹, Maryam Ehteshami², Philippe Bürgisser³, Monique Nijhuis⁴, Lisa Demeter⁵, Sabine Yerly⁶, Jürg Böni⁷, Thomas Klimkait⁸, Ma
Prognostic factors of survival in HIV-infected individuals with progressive multifocal leukoencephalopathy	Nina Khanna¹, Luigia Elzi¹, Nicolas Müller², Christian Garzoni³, Christoph Fux⁴, Matthias Cavassini⁵, Pietro Vernazza⁶, Enos Bernasconi⁷, Manuel B
Patients in Mafeteng on Antiretroviral Therapy (PIMA) - a cross-sectional study of patients receiving antiretroviral treatment (ART) in Lesotho	Claudia Kircher¹, Piet Mc Pherson², Mtate Tsasanyana³, Me Rantequa³, Jan Bergmann¹, Reinhard Brodt⁴, Shlomo Staszewski¹, Tessa Lennemann¹
Todesursachen von HIV-Patienten in der Köln-Bonn Kohorte	Caroline Hertenstein¹, Joerg Janne Vehreschild¹, Jan-Christian Wasmuth², Tim Kümmerle¹, Jürgen Rockstroh², Gerd Fätkenheuer¹
Ongoing syphilis epidemic among HIV-infected men who have sex with men in Austria	Stefanie Gogl¹, Mario Sarcletti², Margret Jöchl³, Armin Rieger⁴, Maria Geit⁵, Bernhard Haas⁶, Ninon Taylor⁷, Manfred Kanatschnig⁸, Robert Zangerle
Trends of transmitted drug resistance in Germany: an update of the German HIV-1 seroconverter cohort	Claudia Kuecherer¹, Barbara Bartmeyer², Kathrin Keeren¹, Claudia Houareau², Christian Kollan², Sybille Somogyi¹, Bernhard Bienek³, Stefan Dupke⁴, Heiko
Transmission of drug resistant HIV in Austria	Margret Jöchl¹, Stefanie Gogl², Armin Rieger³, Mario Sarcletti⁴, Maria Geit⁵, Bernhard Haas⁶, Ninon Taylor⁷, Manfred Kanatschnig⁸, Robert Zangerle
Epidemiology of primary drug resistance in chronically HIV infected patients in Germany	Mark Oette¹, Rolf Kaiser², Thomas Lengauer³, Stefan Reuter⁴, Nadine Sichtig², Gerd Fätkenheuer⁵, Jürgen K Rockstroh⁶, Heribert Knechten⁷, Stefa
Hepatitis B- (HBV) and hepatitis C- (HCV) co-infection in patients with a known date of HIV-infection in the German HIV-1-seroconverter-cohort	Nadine Spielmann¹, Barbara Bartmeyer¹, Claudia Houareau¹, Claudia Kücherer¹, Christina Lindemann¹, Osamah Hamouda¹
Minority quasispecies of drug-resistant viruses in acutely HIV-1 infected patients in Hamburg, Germany: prevalence patterns and time-trends	Hans-Jürgen Stellbrink¹, Christian Noah², Karin Metzner³
Concomitant diseases in HIV-positive persons (PLWHA) in Germany - a comparison between sexes on basis of the KompNet cohort	Klaus Jansen¹, Norbert H. Brockmeyer^1,2, Monika Baudewig³, Ravi Walli³, Burkhard Haastert⁴, Matthias Freiwald⁵, Thomas Harrer⁶, Shlomo Staszewski⁷, B.
Frauenspezifische Risikofaktoren für �frühe“ und �späte“ HIV-Diagnosen in Österreich	Margret Jöchl¹, Stefanie Gogl¹
Identification of a novel recombinant form of HIV-1 in Switzerland	Daniel H Paris^1,2, Roberto F Speck¹, Jürg Böni³
Treatment interruptions (TI) of antiretroviral combination therapy (cART) in the German ClinSurv cohort 2005-2008	Christian Kollan¹, Claudia Houareau¹, Barbara Bartmeyer¹, Andrea Kühne¹, Osamah Hamouda¹, for the ClinSurv Study Group
Epidemiological situation of STI in the border region Vienna/Austria: results of the BORDERNET sentinel surveillance	Klaus Jansen¹, Andreas Gilsdorf¹, Elfriede Steffan², Osamah Hamouda¹, Viviane Bremer¹
HIV patient care under real life conditions: experiences from the southwestern german cohort	Jens Kittner¹, Ana Paula Barreiros¹, Bernd Claus², Martin Däumer³, Kurt Fischer⁴, Georg Friese⁵, Jürgen Lohmeyer⁶, Thomas Rath⁷, Ansgar Rieke
Recent antiretroviral treatment (ART) practice in Germany - results from the ClinSurv multicenter cohort	Christian Kollan¹, Andrea Kühne¹, Barbara Bartmeyer¹, Osamah Hamouda¹, for the ClinSurv Study Group
High influence of migration and sex-work on the epidemiological situation of STI in Vienna/Austria: results of the BORDERNET sentinel-surveillance	Klaus Jansen¹, Andreas Gilsdorf¹, Elfriede Steffan², Osamah Hamouda¹, Viviane Bremer¹
Impact of 44 months cART-dispensing on HIV-care in rural south-central Tanzania	Erik Mossdorf^1,2,3, Geofrey Mwaigomole¹, Evarist Chiweka¹, Patience Kibatala⁴, Christoph Hatz³, Manuel Battegay⁵, Marcel Stoeckle^3,5
The influence of genotypic resistance testing on antiretroviral first-line treatment decision in the German HIV-1-seroconverter-study-group	Claudia Houareau¹, Barbara Bartmeyer¹, Claudia Kücherer², Nadine Spielmann¹, Christian Kollan¹, Christina Lindemann¹, Osamah Hamouda¹, German Serokonverter Stu
Factors associated with adverse pregnancy outcome in HIV positive women: evidence from the Swiss Mother and Child HIV cohort study	Karoline Aebi-Popp¹, Louise Vilén², Tracy Glass³, Olav Lapaire¹, Irene Hoesli¹, Mother and Child HIV Cohort Study
Self-reported history of STI and STI-related utilization of the German health care system by MSM	Axel J. Schmidt¹, Ulrich Marcus¹
The spectrum of malignancies in the era of HAART	Martin Vogel¹, Oliver Friedrich¹, Tobias Höller², Jan-Christian Wasmuth¹, Evrim Anadol¹, Carolynne Schwarze-Zander¹, Bernd Holleczek³, Jürgen Kurt Rockstr
Increasing prevalence of syphilis in MSM with known date of HIV-infection from the German HIV-1 seroconverter study	Ulrich Marcus¹, Claudia Kücherer², Axel J. Schmidt¹, Barbara Gunsenheimer-Bartmeyer¹, Christina Lindemann¹, Nadine Spielmann¹, Osamah Hamouda¹, German HIV-1 Ser
HBV genotype diversity in HIV/HBV co-infected patients in the Swiss HIV cohort	Florian Bihl¹, Gladys Martinetti², Bruno Ledergeber³, Sandrine Estoppey Younes⁴, Rainer Weber³, Pietro Vernazza⁵, Manuel Battegay⁶, Hans Jakob Furrer⁷,
Switching to raltegravir in HIV-infected patients with well controlled viral load - efficacy and safety	Stefan Mauss¹, Ana Milincovic², Florian Berger¹, Julia Henke¹, Guenther Schmutz¹, Petra Hegener¹, Dieter Kuschak³, Stephan Schauseil³, Jospe Mallolas
HIV integrase inhibition - more complex that simply blocking one key viral enzyme function	Séverine Louvel¹, François Hamy², Thomas KIimkait¹
New antiretroviral treatment options with integrase-inhibitors, CCR5-antagonists and second-generation-NNRTI and combination antiretroviral therapy (cART) in the ClinSurv cohort	Barbara Bartmeyer¹, Kollan Christian¹, Kühne Andrea¹, Osamah Hamouda¹, Studiengruppe Klinische Surveillance ClinSurv
Final results from the Connect cohort confirm efficacy and safety of enfuvirtide in a "real life setting "	Olaf Degen¹, Gerd Faetkenheuer², J Bogner³, S Dupke⁴, S Koeppe⁵, S Gute⁶, W Becker⁷, A Tappe⁸, Egbert Wellmann⁸, Hans-Juergen Stellbrink
Treatment of HIV-infected patients with a HAART regimen containing Enfuvirtide and a “second generation” protease inhibitor	Thore Lorenzen¹, Irene Walther¹, Johannes R. Bogner², Jan van Lunzen³, Christoph Schuler⁴, Gerd Fätkenheuer⁵, Peter Gute⁶, Carl-Knut Schewe⁷, Siegfr
Opportunities to assessan optimized salvage regimen in HIV infected triple-class experienced patients by the expert advice system RADATA	Thore Lorenzen¹, Irene Walther¹, Peter Gute², Johannes R. Bogner³, Stefan Mauss⁴, Matthias Stoll⁵, Heribert Knechten⁶, Jürgen Rockstroh⁷, Jan van L
Maraviroc in clinical practice - 24 weeks data	Heribert Knechten¹, Christian Höhn¹, Robert Ehret¹, Frank Wiesmann¹, Martin Hower², Stefan Scholten³, Anton Neuwirth⁴, Wolfgang Köthemann⁴, Pa
Durable efficacy and safety of etravirine in treatment-experienced, HIV-1-infected patients: pooled Week-96 results from the phase-III DUET-1 and DUET-2 trials	J Vingerhoets¹, B Woodfall¹
Safety and efficacy of tenofovir DF (TDF) in combination with 3TC and efavirenz (EFV) in antiretroviral-naïve patients through seven years	Isabel Cassetti¹, Jose Valdez R. Madruga², Arnaldo Etzel³, Jamal Muhamad A.H. Suleiman⁴, Britta Ranneberg⁵, Lijie Zhong⁶, Andrew Cheng⁶, Jeffrey Enejosa⁶,
The 48-week efficacy and safety of switching to fixed dose efavirenz/emtricitabine/tenofovir DF in HIV-1-infected patients receiving HAART	Edwin De Jesus¹, Anton Pozniak², Markus Bickel³, Joel Gallant⁴, Jose Arribas⁵, Yun Zhou⁶, Andrew Cheng⁶, Jeffrey Enejosa⁶
Simplification of therapy (ART) with Efavirenz/Emtricitabine/Tenofovir DF single tablet regimen vs. continued ART in suppressed, HIV-infected patients	B. Young¹, E. de Jesus², J.O. Morales-Ramirez³, Tina Nakonz⁴, J-F. Maa⁵, D. Seekins⁵, A. Farajallah⁵, R. Ebrahimi⁶, J. Flaherty⁶
Safety and tolerability of etravirine (ETR) in hepatitis B and/or C co-infected patients in DUET-1 and 2: 48 week results	Albrecht Stoehr¹, Gerd Fätkenheuer², Klaus Göbels³, Frank-Detlef Goebel⁴, Hans Jäger⁵, Arend Moll⁶, Jürgen Kurt Rockstroh⁷, Dieter Schuster
Langzeitverträglichkeit und -effizienz von Nevirapin als Bestandteil einer HAART	Ivanka Krznaric¹, Stephan Dupke¹
Patient reported outcomes after simplification to a single tablet regimen of Efavirenz (EFV)/Emtricitabine (FTC)/Tenofovir DF (TDF)	S. Hodder¹, K. Mounzer², E. de Jesus³, Tina Nakonz⁴, K. Grimm⁵, A. Farajallah⁵, J. Flaherty⁶
Safety and efficacy of tenofovir in pregnant women	Annette Elisabeth Haberl¹, Richard Linde², Anke Reitter³, Peter Gute⁴, Gaby Knecht⁴, Manfred Mösch⁵, Tessa Lennemann⁶, Gabriele Nisius⁶, Christoph
Kivexa versus Truvada: similar virological outcomes in ART-naïve patients starting a lopinavir/ritonavir-based regimen. 48-week-data from the STAR and STELLA cohorts	Eva Wolf¹, Axel Baumgarten², Bernhard Bieniek³, Stefanie Holm⁴, Martin Hower⁵, Hans Jaeger⁶, Thomas Lutz⁷, Markus Mueller⁸, Wolfgang Schmidt⁹
Efficacy and safety of TDF/FTC-containing first line HAART in clinical practice - two year data from the German outpatient cohort	Jan van Lunzen¹, Gerd Fätkenheuer², Thomas Lutz³, Stephan Klauke⁴, Stefan Mauss⁵, Carl Knud Schewe⁶, Heribert Knechten⁷, Patrick Braun⁷, Lothar Ga
Gutes Ansprechen einer Kombinationstherapie von Trizivir/Tenofovir bei Vorbehandelten über 96 Wochen. CTP-Score vs.1.2 als prädiktives Tool für den Therapieerfolg	Stephan Dupke¹, Bettina Hintsche¹, Christoph Mayr¹, Frank Schlote¹, Arend Moll¹, Felise Krauthausen¹, Daniel Prziwara¹, Dorothea Schleehauf¹, Siegfried
48-wk safety and efficacy of darunavir/ritonavir (DRV/r) in treatment-experienced children and adolescents in DELPHI	P Vis¹, V Sekar¹, B Van Baelen¹, S Spinosa-Guzman¹
Efficient suppression of minority quasispecies of drug-resistant viruses present at primary HIV-1 infection by boosted protease inhibitor containing ART	Karin J Metzner¹, Pia Rauch², Viktor von Wyl¹, Herbert Kuster¹, Jürg Böni³, Rainer Weber¹, Huldrych F Günthard¹
Efficacy and safety of 48 weeks maintenance with once-daily ATV vs ATV/r in suppressed patients after induction with ATV/r	J-F Delfraissy¹, S Moreno², J Sanz-Moreno³, G Carosi⁴, V Pokrovsky⁵, A Lazzarin⁶, G Pialoux⁷, A Balogh⁸, E Vandeloise⁸, I Scheirich⁹
Low nadir CD4 count predicts failure of LPV/r monotherapy (MOST) due to unexpectedly high failure rate in monotherapy arm	Christine Gutmann¹, Milos Opravil², Christoph Fux³, Hansjakob Furrer³, Laurent-Arthur Decosterd⁴, Matthias Cavassini⁴, Sabine Yerly⁵, Bernard Hirschel⁵,
Cost effectiveness analysis of atazanavir versus lopinavir in the treatment of naïve HIV patients in Germany	Per-Olof Thuresson¹, Iris Scheirich², Aljoscha S Neubauer², Bart Heeg¹
Vergleich der Kosten-Nutzen-Relation verschiedener Proteaseinhibitoren bei der Erstlinien-Therapie von HIV-Patienten unter Anwendung der vom IQWIG vorgeschlagenen Methode der Effizienzgrenze	Verena Donatz¹, Erik Smets², Andrew Hill³, Matthias Stoll⁴
Efficacy and safety by baseline HIV-RNA and CD4-count in treatment-naive patients treated with Atazanavir/r and Lopinavir/r in the CASTLE study	J Uy¹, R Yang¹, A Thiry¹, J Absalon¹, A Farajallah¹, J Maa¹, E Grützner², I Scheirich², D McGrath¹
Susceptibility of diverse HIV-1 patient isolates to the maturation inhibitor, bevirimat, is setermined by clade-specific polymorphisms in Gag CA-SP1	Thomas Klimkait¹, Karl Salzwedel², Severine Louvel¹, M Sakalian², M Reddick², C Finnegan², D Martin², S Mc Callister², Francois Hamy¹, G Al
Once-daily draunavir used in routine clinical care produces trough Darunavir-drug-concentrations in excess of 30x the protein-corrected (PC)EC₅₀ for wild-type HIV	Claire Robertson¹, A. N. Jayasuriya¹, C. Smith², N. Dufty¹, A. Berry¹, C. Stradling¹, Steve Taylor¹
Lopinavir/ritonavir plus atazanavir in comparison to lopinavir/ritonavir plus nucleoside analogues (zidovudin plus lamivudin) - the LORAN-trial, A Phase III-study	Kai Ulbricht¹, Matthias Stoll¹, Georg M. Behrens¹, Bernd Salzberger², Heiko Jessen³, Arne Jessen³, Birger Kuhlmann⁴, Hans Heiken⁴, Andreas Trein⁵
Long term outcome of 8 infants, which started treatment with 2 NRTI + Nelfinavir in the first year of life	Bernd Buchholz¹, Steffen Hien¹, Matthias Beichert¹, Matthias Dürken¹, Horst Schroten¹
Health-related quality of life (HRQoL) improvement in antiretroviral-naive HIV-infected patients on atazanavir/r or lopinavir/r regimens: week 24 results from AI424138	J Su¹, J Absalon¹, M Mancini¹, U Iloeje¹, N Strobl², I Scheirich², D McGrath¹
Gender differences in ART-naive patients initiating a lopinavir/ritonavir-based regimen. 48 week data from the German STAR and STELLA cohorts	Christine Koegl¹, Axel Baumgarten², Bernhard Bieniek³, Stefanie Holm⁴, Martin Hower⁵, Hans Jaeger⁶, Thomas Lutz⁷, Markus Mueller⁸, Wolfgang Schmidt
Starting a Lopinavir/r-based regimen in ART-naive patients improves quality of life. 48-week data from the German STAR and STELLA cohorts	Christine Koegl¹, Axel Baumgarten², Bernhard Bieniek³, Stefanie Holm⁴, Martin Hower⁵, Hans Jaeger⁶, Thomas Lutz⁷, Markus Mueller⁸, Wolfgang Schmidt
Safety analysis of darunavir/r (DRV/r): combined data from randomised Phase II and Phase III studies	Gerd Fätkenheuer¹, Keikawus Arasteh², Johannes Bogner³, Frank-Detlef Goebel⁴, Thomas Harrer⁵, Hans Jäger⁶, Jörg-Andres Rump⁷, Dieter Schuster^8<
German cost-efficacy analysis to achieve full virological suppression for treatment experienced HIV infected patients in the DUET trials	Matthias Stoll¹, Verena Donatz², Silas Martin³, Andrew M Hill⁴
HIV RNA levels six months after antiretroviral therapy initiation predict subsequent survival and retention of HIV-1-infected individuals in Sub-Saharan Africa	Maria Cristina Marazzi¹, Leonardo Palombi², Ersilia Buonomo², Paola Scarcella², Giovanna Paturzo³, Anna Maria Doro Altan², Susanna Ceffa³, Dieter Wanderlein⁴,
Retrospektive Datenerhebung über den Zeitpunkt des Therapiebeginns bei HIV positiven Frauen in zwei Zentren Deutschlands von 1995-2008	Ivanka Krznaric¹, Alexander Zoufaly², Sandra Hertling³
Antiretrovirale Therapie bei einem extremen Frühgeborenen	David Endress¹, Richard Linde², Doris Fischer³, Elisabeth Förster-Waldl⁴, Wolfhart Kreuz², Andreas Lischka¹, Christoph Königs²
Atazanavir plasma concentrations substantially decreased in HIV-1 infected adults taking concomitantly methadone oral solution in a daily observed therapy	Annette Haberl¹, Christoph Stephan¹, Manfred Mösch², Gabi Nisius¹, Tessa Lennemann¹, Pavel Khaykin¹, Michael Kurowski³, Schlomo Staszewski¹, Reinhard Bro
Pharmacokinetics and dose selection of etravirine (ETR) in HIV-infected children between 6 and 17 years, inclusive	Christoph Königs¹, Cornelia Feiterna-Sperling², Susanna Esposito³, Carlo Giaquinto⁴, Thomas Kakuda⁵, Rekha Sinha⁶, Rebecca Mack⁵, Katrie Janssen⁶,
Prevalence of virologic failure in HIV-1-infected patients treated with antiretroviral therapy (ART) - results from a German multicenter cohort-study (VIREMIA)	Axel Baumgarten¹, Stephan Klauke², Knud Schwere³, Christoph Mayr⁴, Hans Jäger⁵, Pavel Khaykin⁶, Cam-Tuan Tran⁷, Markus Bickel⁶
Veränderungen des HIV-1-Mutationsprofils vor Therapiebeginn in Abhängigkeit von der Zeit	Stefan Reuter¹, Rolf Kaiser², Mark Oette³, Melanie Balduin², Björn Jensen¹, Dieter Häussinger¹, Nadine Sichtig²
Use of tenofovir disoproxil fumarate (TDF) during pregnancy: an analysis from the Antiretroviral Pregnancy Registry (APR)	Bruce Olmscheid¹, Sandra Hertling², Sherry Zhang¹
Efficacy of a computerised physician reminder system to control CHD risk factors in HIV-patients receiving cART (Swiss HIV Cohort Study)	Heiner C. Bucher¹, Martin Rickenbach², James Young¹, Tracy Glass¹, Yannick Valley², Enos Bernasconi³, Matthias Cavassini⁴, Christoph Fux⁵, Véronique
Prevalence of minority HIV-1 NNRTI drug resistance mutation K103N in antiretroviral treatment-naïve patients	Patrick Braun¹, Robert Ehret¹, Christian Höhn¹, Frank Wiesmann¹, Heribert Knechten¹
Tenofovir- and protease inhibitor-use are associated with an Increased prevalence of proximal renal tubular dysfunction in the SHCS	Christoph Andreas Fux¹, Milos Opravil², Matthias Cavassini³, Alexandra Calmy⁴, Ben Spycher⁵, Barbara Hasse², Patrick Schmid⁶, Marcel Stöckle⁷, Vanin
12 h pharmacokinetics in HIV mono- and HIV/HCV co-infected patients	Martin Vogel¹, Norbert Bertram², Jan-Christian Wasmuth¹, Christoph Wyen³, Esther Voigt¹, Carolynne Schwarze-Zander¹, Thomas Sudhop⁴, Gerd Fätkenheuer³
Impact of resistant HIV on first line treatment response in therapy naive patients of the German HIV-1-seroconverter cohort	Barbara Bartmeyer¹, Claudia Houareau¹, Claudia Kücherer², Christian Kollan¹, Johanna Werning¹, Osamah Hamouda¹, Deutsche HIV-1 Seroconverter Studiengruppe
Quantitative and qualitative mtDNA-lesions with mitochondrial dysfunction in multiple organs after HAART-associated fatal lactacidosis	Jan Thoden¹, Dirk Lebrecht¹, Nils Venhoff¹, Jens H Neumann², Klaus Müller³, Ulrich A Walker¹
Coronary heart disease and risk factors in HIV-1-infected patients in correlation to abacavir treatment	Thomas Harrer¹, Almut Taubald¹, Ellen G. Harrer¹, Christina Schaub-Koch¹, Anja Reisch¹, Sandra M. Müller¹, Bernd Spriewald², Mohamed Marvan³, Frank
Detection of abacavir hypersensitivity by ELISpot method	Stefan Esser¹, Robert Jablonka¹, Falko M. Heinemann², Monika Lindemann²
A German cohort of 54 HIV and LPV/r exposed pregnancies - pharmacokinetics, placental transfer and pregnancy outcome	Milena Sovric¹, Andrea Gingelmaier¹, Ralph Kaestner¹, Tobias Weissenbacher¹, Ionnis Mylonas¹, Klaus Friese¹
Frequent pyridoxal phosphate (PLP) inadequacy associated with the use of RTV-boosted protease inhibitors	Hans-Jürgen Stellbrink^1,2, Andreas Lämmel², Christian Noah²
Transmission of a highly RT-and protease-inhibitor resistant virus demonstrates the importance of resistance analysis prior to initiation of HAART	Thomas Harrer¹, Klaus Korn², Hauke Walter², Sandra M. Müller¹, Werner Matek³, Ellen G. Harrer¹, German Competence Network for HIV/AIDS
Frequency of lipodystrophy in a large observational cohort using either LPV/r or EFV	Jan van Lunzen¹, Ramona Volkert-Pauli², Stefan Hansen³, Martin Hower⁴, Clemens Scheidegger⁵, Antonius Mutz⁶, Andreas Trein⁷
The definition "acute" does not influence SVR in HIV-positive individuals treated with pegylated interferon +/- interferon after acute HCV infection	Martin Vogel¹, Axel Baumgarten², Kevin Ummard³, Michael Rausch⁴, Knud Schewe⁵, Christoph Mayr⁶, Dietmar Schranz⁷, Albert Theisen⁸, Heiko Jessen⁹
Leberparenchymschaden bei HIV-1-Monoinfizierten unter antiretroviraler Therapie (ART) und chronischer Transaminasenerhöhung	Patrick Ingiliz¹, Marc-Antoine Valantin², Claudine Duvivier³, Fadia Medja⁴, Stephanie Dominguez³, Frédéric Charlotte⁵, Roland Tubiana³, Thierry Poynard
Methicillin resistant Staphylococcus aureus and ESBL-producing Escherichia coli, Klebsiella pneumoniae and Klebsiella oxytoca isolated from HIV infected inpatients	Hartmut Stocker¹, Bettina Eberspaecher², Hubert Schulbin¹, Christian Traeder¹, Sonja Swidsinski³, Keikawus Arasteh¹
Vergleich von TST, QuantiFERON-Gold In-Tube und T-Spot.TB bei HIV-Patienten	Christoph Stephan¹, Timo Wolf¹, Udo Götsch², Oswald Bellinger², Gabriele Nisius¹, Gerhard Oremek³, René Gottschalk², Sonja Stark², Hans-Reinha
Anales Dysplasiescreening bei HIV-infizierten Frauen	Andrea Gingelmaier¹, Tobias Weissenbacher¹, Kästner Ralph¹, Bernd Kost¹, Thomas Grubert², Sovric Milena¹, Florian Bergauer¹
Streptococcal proctitis resembling gonorrhoea in HIV infected men who have sex with men	Anja Potthoff¹, Alexander Kreuter¹, Norbert H. Brockmeyer¹, Competence Network for HIV/AIDS
*Anorectal Chlamydia trachomatis* infections in Swiss HIV-infected homosexual men**	Thanh Dang¹, Katia Jaton², Markus Flepp³, Helen Kovari⁴, Jonh-Marc Evison⁵, Jan Fehr⁶, Patrick Schmid⁷, Emmanuelle Boffi El Amari⁸, Massimo Odorico
Incidence of bacterial, fungal or viral co-infection in HIV-positive individuals with PCP: a retrospective analysis of the AVK cohort	Christian Traeder¹, Susann Kowoll¹, Hartmut Stocker¹, Keikawus Arastéh¹
Wirksamkeit einer anti-retroviralen Therapie (HAART) bei Patienten mit HBV-HIV Koinfektion	Kosi Lana¹, Thomas Reiberger¹, Katharina Pfistershammer², A. Rieger², Markus Peck-Radosavljevic¹
Hepatitis C coinfection in HIV-infected patients - evidence for considerable undertreatment	Axel Baumgarten¹, Christian Hoffmann², Lutwin Weitner², Arend Moll³, Christiane Cordes⁴, Frank Schlote⁵, Heinz-August Horst⁶, Siegfried Köppe⁷, Bet
Antivirale Effektivität von Interferon bei immunkomprimierten HCV Patienten nach Lebertransplantation oder mit HIV Koinfektion	Thomas Reiberger¹, Susanne Rasoul-Rockenschaub², Peter Ferenci¹, Armin Rieger³, Markus Peck-Radosavljevic¹
Ribavirin-Plasmakonzentrationen in der antiviralen Therapie der chronischen Hepatitis C	Hartwig Klinker¹, Werner Heinz¹, Isabell Trebesch¹, Christine Guhl¹, Andreas Trein², Gudrun Tossing³, Peter Langmann⁴
Simultane Radiochemotherapie des Analkarzinoms bei HIV-positiven Patienten unter HAART	Ingeborg Fraunholz¹, Anette Haberl², Claus Rödel¹
Beschleunigte Fibroseprogression und portale Hypertension bei HIV-HCV koinfizierten Patienten mit niedrigem CD4⁺ Nadir	Thomas Reiberger¹, Arnulf Ferlitsch¹, Wolfgang Sieghart¹, Florian Breitenecker², Armin Rieger², Brigitte Schmied³, Markus Peck-Radosavljevic¹
The relevance of CMV viremia, in the HAART era	Emmanuelle Boffi El Amari¹, Christophe Combescure¹, Sabine Yerly¹, Alexandra Calmy¹, Laurent Kaiser¹, Bernard Hirschel¹, Swiss HIV Cohort Study
High risk of mamma carcinoma in HIV infected men	Anja Potthoff¹, Klaus Jansen², Martin Doerler¹, Claudia Michalik³, Norbert H. Brockmeyer¹, Competence Network for HIV/AIDS
HBV-markers in HIV-treatment naive patients from the RESINA-cohort	Frank Wilhelm¹, Nadine Sichtig¹, Eugen Schülter¹, Jens Verheyen¹, Herbert Pfister¹, Mark Oette², Rolf Kaiser¹, Gerd Fätkenheuer³, Thomas Lengauer
High dose chemotherapy followed by autologous stem cell transplantation in HIV-related lymphoma or germ cell tumor: the Munich experience	Marcus Hentrich¹, Tim Röhnisch², Arthur Gerl³, Clemens Scheidegger⁴, Eva Jägel-Guedes⁵, Christoph von Schilling⁶, Thomas Sternfeld⁷, Xaver Schiel⁸
Rupia syphilitica bei HIV-positiver Patientin	Ahmad Jalili¹, Martin Mosleh¹, Katharina Pfistershammer¹, Armin Rieger¹
Untersuchung zur Bedeutung der Syphilis bei MSM mit HIV Ko-Infektion	Alexander Bubnov¹, Janine Zweigner², Carmen Zedlack¹, Heiko Jessen¹
Conservative antibiotic management of infected totally implantable venous access devices (TIVAD). A retrospective analysis of the AVK cohort	Marlen Wieczorek¹, Christian Traeder¹, Dirk Hampf¹, Keikawus Arastéh¹
Meningomyelitis complicating primary HIV infection	Hubert Schulbin¹, Hartmut Stocker¹, Siegfried Köppe², Peter Kreckel², Keikawus Arasteh¹
Identical liver fibrosis in a cohort of HIV/HCV-coinfected patients on HAART as compared to HIV-negative HCV-patients assessed by transient elastography	Frank Grünhage¹, Jan-Christian Wasmuth², Simon Herkenrath², Natascha Vidovic³, Georg Goldmann³, Jürgen Rockstroh², Frank Lammert¹, Johannes Oldenburg
Severe Leucencephalopathy as aseptic form of immune reconstitution inflammatory syndrome in the brain in Caucasian and African patients	Adrian Ringelstein¹, Christian Oelschlaeger², Ingo W Husstedt², Christian Mathys¹, Andreas Saleh¹, Gabriele Arendt³
Autonomous nervous system activity and glucose metabolism in HIV-patients receiving antiretroviral therapy	Maximiliane Wiese¹, Michael Kaspari¹, Ulrike Möbius¹, Reinhold E Schmidt¹, Georg M Behrens¹
Do changes of fractional anisotropy predict loss of cognitive functions in HIV patients?	Bianca Stubbe-Dräger¹, Michael Deppe¹, Siawoosh Mohammadi¹, Harald Kugel², Nora Gregor¹, Stefan Evers¹, Erich-B. Ringelstein¹, Gabriele Arendt³, St
Characterization of revertant HIV from patients in the German seroconverterstudy: viral fitness and in vitro selection of AZT resistance	Kathrin Keeren¹, Livia Schünadel¹, Eva Brandt¹, Sybille Somogyi¹, Klaus Fischer², Bettina Hintsche³, Gerd Klausen³, Heiko Jessen⁴, Barbara Bartmey
Delayed detection of HIV seroconversion using a 4^th generation HIV rapid test	Gerrit Mohrmann¹, Hans-Jürgen Stellbrink², Christian Noah¹
Predictors for CXCR4-tropism: CD4-nadir and the use of the enhanced sensitivity (ES) trofile assay	Eva Wolf¹, Patrick Braun², Lothar Schneider³, Anna Balogh¹, Heribert Knechten², Martin Karwat⁴, Franz Mosthaf⁵, Albrecht Ulmer⁶, Robert Ehret²
HIV coreceptor tropism in treatment-naive patients newly diagnosed at a late stage of HIV-infection	Benedikt Simon¹, Armin Rieger², Mario Sarcletti³, Brigitte Schmied⁴, Elisabeth Puchhammer-Stöckl¹
Selection of peptide ligands for CXCR4-using HIV-1 by the phage display technology	Ralf Duerr¹, Kalle Möbius², Oliver Sander³, Jutta Eichler², Ursula Dietrich¹
Performance of genotypic coreceptor measurement using geno2pheno[coreceptor] in B- and non-B HIV subtypes in a large cohort of therapy-experienced patients	Hauke Walter¹, Eva Wolf², Patrick Braun³, Martin Däumer⁴, Alexander Thielen⁵, Christian Noah⁶, Nadine Sichtig⁷, Harm Müller⁸, Martin Stü
Development of antigen-based capture ELISA for serodiagnosis of GB Virus C infection in HIV patients	Mandy Richter¹, Susan Jung¹, Bernhard Fleckenstein¹, Heide Reil¹
Underestimation of HIV-1 RNA levels in a commercial real-time PCR assay: reasons and consequences	Klaus Korn¹, Benedikt Weißbrich², Cornelia Henke-Gendo³, Albert Heim³, Ninon Taylor⁴, Ramona Pauli-Volkert⁵, Josef Eberle⁶
Fallbericht: Anhaltend grenzwertiger Westernblot trotz gesicherter HIV-Infektion mit übertragener Multiresistenz	Jens Martin Kittner¹, Martin Däumer², Bernhard Thiele², Thomas Mertes³, Ana-Paula Barreiros¹, Marcus Schuchmann¹, Ansgar Rieke⁴
Longitudinal modeling of the influence of genetic variants identified through genome-wide analyses and antiretroviral therapy to dyslipidemia in HIV-infected patients	Margalida Rotger¹, Patrick Taffé², Amalio Telenti¹, Philip Tarr³, Swiss HIV Cohort Study
Integration of structured counseling for smoking cessation in HIV outpatient care	Milo Huber¹, Rainer Weber¹, Bruno Ledergerber¹, and the SHCS
Reprogramming of CD8⁺ T cells with an HIV-1-specificity by TCR-RNA electroporation	Christian Hofmann^1,2, Thomas Harrer¹, Kathrin Eismann¹, Silke Bergmann¹, Verena Kubesch², Ellen Harrer¹, Gerold Schuler², Jan Dörrie², Niels Schaf
Kinderwunschberatung bei HIV-infizierten Frauen	Andrea Gingelmaier¹, Katja Wiedenmann¹, Ralph Kästner¹, Milena Sovric¹, Marianne Müller¹, Ulrike Sonnenberg-Schwan², Katharina Weizsäcker³
Erste HIV-1/2 Doppelinfektion in Österreich - ein Fallbericht	Wolfgang Prammer¹, Josef Eberle², Walter Aichinger¹
What do HIV-infected patients die of today?	Silja Bühler¹, Julia Söllner¹, Ulrich Seybold¹, Johannes R Bogner¹
Der Beginn der Transmissionsprophylaxe in der 32. Schwangerschaftswoche scheint zu spät zu sein - Daten aus Hamburg	Sandra Hertling¹, Karen Olah², Irene Walther², Rainer Laux³, Rainer Ganschow⁴, Mareike Sornsakrin⁴, Stefan Hansen⁵, Kristin Lauterbach⁶, Sonja Gudowius
Virological medical quality management - 9 years follow-up	Patrick Braun¹, Christian Höhn¹, Frank Wiesmann¹, Robert Ehret¹, Heribert Knechten¹
Successful HIV1-Post-Expositionprophylaxis in 7 extremely premature newborns (birth weight < 1500g) with several risks of HIV1-transmission	Steffen Hien¹, Bernd Buchholz¹, Matthias Beichert², Thomas Schaible¹, Horst Schroten¹
Single balloon enteroscopy (SBE): findings in the small intestine in HIV infected individuals: a prospective study of the AVK cohort	Julia Brümmer¹, Christian Träder¹, Keikawus Arastéh¹
10 Jahres-Jubiläum von HIVmobil: Verein für HIV-spezifische medizinische Hauskrankenpflege und Langzeitpflege sowie Sozialbegleitung für Menschen mit HIV-AIDS in Wien	Wolfgang Steflitsch¹, Elisabeth Maurer², Eva Stifter², Beate Dannoritzer², HIVmobil
Late HIV presentation at the Chronic Diseases Clinic (CDCI) of the rural St. Francis Designated District Hospital, Ifakara Tanzania	Nadja Heuer^1,2,3, Marcel Stoeckle^2,4, Boniphace Jullu⁵, Rehema Mchomvu¹, Penelope Vounatsou², Patience Kibatala⁶, Hansjakob Furrer⁷, Manuel Battegay⁴, C
Entwicklung einer Hochqualitätsversorgung in der ambulanten Betreuung von HIV infizierten Patienten in Kamerun	Stefan Schmiedel¹, Torsten Feldt^2,3,4,5, Nchang Taka⁶, Jonah Wefuan⁶, Gerd Dieter Burchard^1,2, Jan van Lunzen¹
3OD - once daily (OD) TDF-containing HAART in HIV-1-infected former IVDU patients receiving opiate substitution: efficacy, tolerability and adherence	Stefan Esser¹, Schlomo Staszewski², Annette Haberl², Fiona Mulcahy³, Jörg Gölz⁴, Andreas Körber¹, Britta Ranneberg⁵, Lothar Gallo⁵, Thoma
Experience patients treated by outpatient clinics or by private practitioners differing treatment characteristics and clinical outcomes in Germany?	Klaus Jansen¹, Norbert H. Brockmeyer¹, Burkhard Haastert², Axel Baumgarten³, A. Stoehr⁴, Georg Behrens⁵, Hans Jaeger⁶, Helmut Hartl⁷, A. Mutz⁸
HIV- positive Frauen können auch in Deutschland vaginal gebären - Erfahrungen mit 50 vaginal intendierten Geburten 2001 bis 2008	Ralph Kästner¹, Andrea Gingelmaier², Milena Sovric², Marianne Müller², Ulrike Sonnenberg-Schwan³, Weizsäcker Katharina⁴
Training and education programme in the European AIDS Treatment Network NEAT	David Hans-U. Haerry¹, Manuel Battegay¹, Stefano Vella²
Ein Praxisprogramm zur Unterstützung der Therapiebereitschaft und Adherence bei Menschen mit HIV	Susanne Stoelzl¹, Dunja Nicca¹, Helene Weyermann¹, Patrick Schmid¹, Pietro Vernazza¹
Distinct viral interference mechanisms by different GBV-C proteins on HIV replication	Kristin Hänel¹, Susan Jung¹, Holger Wend¹, Bernhard Fleckenstein¹, Heide Reil¹
*Uncoupling gag and pol reading frames reveals p6�s role as spacer protein in HIV**	Andreas Leiherer¹, Christine Ludwig¹, Ralf Wagner¹
Einfluss des CTLA4+49A>G Polymorphismus auf das Ansprechen auf eine HCV spezifische Therapie bei HIV-positiven Patienten mit einer akuten Hepatitis C	Benjamin Krämer¹, Martin Vogel¹, Hans Dieter Nischalke¹, Monika Michalk¹, Tilman Sauerbruch¹, Ulrich Spengler¹, Jürgen Rockstroh¹, Jacob Nattermann¹
Is the cellular RNA helicase DDX3 a new potential antiviral target for HIV-1?	Sandra Beermann¹, Giovanni Maga², Ursula Dietrich¹
Mitogenic and adjuvant properties of a multimeric CD40 ligand variant on the surface of HIV-1 C-Clade Pr55^gag VLP	Simon Bredl¹, Josef Köstler¹, Jens Wild¹, Ralf Wagner¹
Sequence and structure information from V3 as basis for a sensitive genosorting method to determine HIV coreceptor use	Heinz Stucki¹, Sarah Wagner¹, Vincent Vidal², François Hamy², Thomas Klimkait¹
Influence of major protease inhibitor resistance mutations on CTL recognition	Sandra Michaela Müller¹, Silke Bergmann¹, Pia Rauch¹, Kathrin Eismann¹, Angela Hückelhoven¹, Jennifer Etschel¹, Bernd Spriewald², Ellen Harrer¹
Relocation and higher apoptosis of plasmacytoid dendritic cells in lymphoid tissues of HIV-1 infected patients	Clara Lehmann¹, Norma Jung¹, Jan van Lunzen², Gerd Fätkenheuer¹, Fabio Romerio³, Pia Hartmann¹
Interference with the genome of HIV as therapeutic means to block infection	Verena Oberhauser¹, Wilfried Posch¹, Doris Wilflingseder¹, Brigitte Müllauer¹, Stefan Piper², Birgit Werner², Thomas Lindhorst², Holger Bock², Heri
Expansion of CD56-CD16+ NK cells in HIV infection correlates with differential expression patterns of CCR7 and CD57	Henoch Hong¹, Johanna Eberhard¹, Phillip Keudel¹, Nupur Bhatnagar¹, Reinhold E. Schmidt¹, Dirk Meyer-Olson¹
Inhibition of HIV-1 replication by interference with the ESCRT-I subunit Tsg101	Ilona Hauber¹, Jan Chemnitz¹, Birgit Schäfer¹, Joachim Hauber¹
GB Virus C die biologische Alternative zu Maraviroc, T20 & Co	Susan Jung¹, Heide Reil¹
Reduction of HIV infectivity by GB Virus C anti-E2 antibodies	Susan Jung¹, Norbert Donhauser¹, Bernhard Fleckenstein¹, Heide Reil¹
Identification of PD-1 as a unique marker for discordant immune response in HIV infected patients	Katharina Pfistershammer¹, Armin Rieger¹, Peter Steinberger², Norbert Kohrgruber^1,3
Mitochondrial DNA depletion, mitochondrial dysfunction and peripheral lipoatrophy	Metodi V Stankov¹, Reinhold E Schmidt¹, Georg M Behrens¹
HIV-1 Vpr inhibits type I interferon production by plasmacytoid dendritic cells (pDCs) and impairs pDC-NK cell crosstalk in vitro	Henoch Hong¹, Nupur Bhatnagar¹, Ulrich Schubert², Matthias Ballmaier³, Thorsten Volgmann⁴, Reinhold E. Schmidt¹, Hans Heiken¹, Dirk Meyer-Olson¹
Design of highly efficient fluorescent hydrolysis probes for real-time PCR of HIV-1 nucleic acids with broad cross-clade coverage	Claudia Althaus¹, Sara Gianella¹, Philip Rieder¹, Viktor Von Wyl¹, Barbara Niederöst¹, Beda Joos¹, Huldrych F. Günthard¹, Marek Fischer¹
Combating drug resistance - antiretroviral activity and immune function in presence of hypusination inhibitors	Philip Hartjen¹, Marcel Krepstakies², Silke Kummer¹, Ilona Hauber², Joachim Hauber², Jan van Lunzen¹
Accumulation of terminally differentiated cells in the CD4+ T-cell population of immunological non-responders	Eva Katharina Meuer¹, Sandra Winter¹, Norma Jung¹, Jan Rybniker¹, Gerd Fätkenheuer¹, Pia Hartmann¹
Parameters of soluble immune activation in vivo correlate negatively with the proliferative capacity of PBMC in vitro in HIV-infected patients	Katharina Kurz¹, Christine Winkler², Mario Sarcletti³, Nikolaus Romani³, Zoltan Banki⁴, Susanne Ebner³, Dietmar Fuchs², Robert Zangerle³
Mucosal barrier defect and infiltration with CD4+, CD8+, and perforin+ cytotoxic T cells in early acute HIV infection	Hans-Jörg Epple¹, Christoph Loddenkemper², Kristina Allers¹, Michael Fromm³, Jörg-Dieter Schulzke^1,4, Martin Zeitz¹, Thomas Schneider¹
The potential of the Equine Herpes Virus - 1 (EHV-1) vector system as HIV-1 vaccine under safety aspects	Nicole Fiedler¹, Helga Hofman-Sieber², Jens Wild¹, Josef Köstler¹, Karsten Tischer³, Jens von Einem⁴, Nikolaus Osterrieder³, Ralf Wagner¹
Der Zunahme der Ko-Expression von CD38 und PD-1 auf HIV-spezifischen CD8-T-Zellen folgt ein Anstieg der Viruslast	Thomas Vollbrecht¹, Heike Brackmann¹, Nadja Henrich¹, Jörg Roling¹, Ulrich Seybold¹, Frank D Goebel¹, Johannes R Bogner¹, Rika Draenert¹
Frequency and impact of drug resistance mutations in previously naïve patients infected with B and non-B HIV-1	Markus Bickel¹, Gundolf Schuettfont¹, Christoph Stephan¹, Stephan Klauke², Thomas Lutz², Annette Haberl¹, Reinhard Brodt¹, Schlomo Staszewski¹, Pavel K
Display of HIV-1 envelope epitopes using the mucosal adjuvant Cholera toxin B as a carrier on virus like particles	Ruth Kapzan¹, Alexander Kliche¹, Ralf Wagner¹
Role of organic cation transporters in pathogenesis and therapy of HIV-infection	Norma Jung¹, Clara Lehmann¹, Andrea Rubbert¹, Gerd Fätkenheuer¹, Pia Hartmann¹, Dirk Taubert²
Uridine supplementation with Mitocnol attenuates mitochondrial cardiomyopathy induced by zidovudine and zalcitabine	Kerstin Balcarek¹, Dirk Lebrecht¹, Ana C Venhoff¹, Catherine Deveaud², Bertrand Beauvoit², Jacques Bonnet², Jan-Bernd Kirschner³, Klaus Müller⁴, Nil
Impact of zidovudine on adipogenesis	Metodi Stankov¹, Reinhold E Schmidt¹, Georg MN Behrens¹
Soluble CD40 ligand (sCD40L) reduces type I interferon production in HIV-infected subjects after stimulation with CpG oligodeoxynucleotides	Norbert Donhauser¹, Martin Helm², Kathrin Pritschet¹, Philipp Schuster¹, Moritz Ries¹, Klaus Korn¹, Sigrun Smola-Hess³, Jörg Vollmer⁴, Barbara Sch
Instability of HIV-1 antibodies in filter-dried plasma samples stored at room temperature: consequences for its use in incidence tests	Stephan Loschen¹, Kristin Strohschein¹, Christopher Drewell¹, Jörg Bätzing-Feigenbaum², Ruth Zimmermann², Osamah Hamouda², Claudia Kücherer¹
Selective expansion of CD56(-)/CD16(+) NK cells in HIV/HCV-coinfection is associated with increased expression of HLA-DR and CD38	Phillip Keudel¹, Henoch Hong¹, Johanna Eberhard¹, Nupur Bhatnagar¹, Margot Zielinska-Skowronek¹, Julian Schulze zur Wiesch², Jan van Lunzen², Reinhold E. Schmidt¹
CD4 receptor density on CD4+ T cells is decreased in HIV+ patients with faster disease progression	Annette Audigé¹, Patrick Taffé², Martin Rickenbach², Pietro Vernazza³, Manuel Battegay⁴, David Nadal⁵, Roberto F. Speck¹, Swiss HIV Cohort Study
Identification of subdominant CD8+ responses selecting CTL escape mutations in Gag that Impair HIV replication	Arne Schneidewind^1,2, Christian Boutwell¹, Zabrina Brumme¹, Mark Brockman¹, Hendrik Streeck¹, Chanson Brumme¹, Katherine Kane¹, Bruce D Walker¹, Marcus
T-regulatory cells and T-cell activation in chronic HIV infection	Christian Raphael Kahlert¹, Reinhard Maier², Burkhard Ludewig², Pietro Vernazza¹
Event-related potentials and cerebrospinal fluid markers during HIV-associated neurocognitive disorder	Katrin Biehl¹, Thorsten Nolting², Eleni Koutsilieri³, Peter Young¹, Doris Reichelt⁴, Gabriele Arendt², Stefan Evers¹, Ingo W. Husstedt¹, German Competen
Glycosylation and processing of inhibitory C-peptides within the secretory pathway	Andreas Volk¹, Joerg Kahle¹, Mina Petkova¹, Lisa Egerer¹, Dorothee von Laer¹
Novel concepts for HIV-1 therapy: targeting the interaction of the HIV-1 export factor Rev and its cellular cofactor Sam68	Patricia Skoczylas¹, Benedikt Asbach¹, Ralf Wagner¹
Characterization of a chemokine receptor CCR5-negative T cell line to determine the human immunodeficiency virus type 1 phenotype	Dorothea Binninger-Schinzel¹, Benjamin Kraus², Daniela Müller¹, Birgit Krause², Britta Neumann², Gudrun Winskowsky², Timo Wolf³, Reinhard Brodt³, Albrecht
Einfluss der HCV-Koinfektion auf die Expression von sog. “Todes-Rezeptoren“ und deren korrespondierenden Liganden auf CD4⁺ T-Zellen bei HIV-positiven Patienten	Christian Körner¹, Felix Tolksdorf¹, Benjamin Krämer¹, Daniela Schulte¹, Martin Coenen¹, Hans-Dieter Nischalke¹, Jacob Nattermann¹, Jürgen K. Rockstr
GBV-C coinfection in the Bonn HIV cohort: impact on cytokine profile	Carolynne Schwarze-Zander¹, Markus Neibecker¹, Evrim Anadol¹, Jan-Christian Wasmuth¹, Martin Vogel¹, Ulrich Spengler¹, Juergen Kurt Rockstroh¹
Uridine supplementation with Mitocnol antagonizes antiretroviral nucleoside analogue-induced mitochondrial peripheral and cerebral neuropathy in vivo	Dirk Lebrecht¹, Catherine Deveaud², Jacques Bonnet², Jan-Bernd Kirschner³, Klaus Müller⁴, Nils Venhoff¹, Ulrich A Walker⁵
Isolation and characterization of scFv's from HIV non-progressors (LTNP/EC)	Maria Hertje¹, Zhou Mingkui¹, Sascha Antoni², Michael Hust³, Stefan Dübel³, Berta Rodes⁴, Vincent Soriano⁴, Markus Bickel⁵, Ursula Dietrich^1<
Interferon-g-mediated pathways and proliferation of HIV-infected peripheral blood mononuclear cells	Katharina Kurz-Schroecksnadel¹, Christiana Winkler², Ernst R. Werner², Mario Sarcletti³, Nikolaus Romani³, Susanne Ebner³, Dietmar Fuchs², Robert Zangerle⁴
Fungal toxins stimulate HIV infection and replication	Cornelia Speth¹, Magdalena Hagleitner¹, Günter Rambach¹, Iradj Mohsenipour²
Pharmacogenetics and personalized care in HIV disease	Amalio Telenti¹
Use of resistance data to select treatment regimen: Guidelines and reality	Huldrych Günthard¹
Individualized Therapy - Therapy for Individual	Jürgen Rockstroh¹
HIV-therapy tomorrow; HIV-therapie morgen	Hansjakob Furrer¹
Activation of myeloid cells, triggered by viral replication but not microbial translocation, correlates with disease progression in SIV-infected macaques	Christoph Leinert¹, Ulrike Sauermann¹, Dietmar Fuchs², Thomas Schneider³, Christiane Stahl-Hennig¹, Sieghart Sopper¹
Immunaktivierung und Alterungsprozesse bei HIV	Georg Behrens¹
Immunologische Ziele der Therapie und neue Therapieformen	Jan van Lunzen^1,2
Global drug policy, the HIV/IDU epidemic in Aastern Europe and Central Asia, and the critical need to scale up opioid substitution therapy	Craig McClure¹
Lessons from partnerships Switzerland - Central Asia	Jakob Huber¹
PrEP and Microbicides - new approaches to HIV-prevention	Thomas Mertenskoetter¹
Progress in AIDS Vaccine Development	Frans van den Boom¹
Invasive Fungal Infetions in the Immuno-deficient Patient	Thomas Grünewald
Changing Epidemiology and Consequences for Prevention	Ulrich Marcus